• FDA Accepts sNDA for Tyvaso from United Therapeutics americanpharmaceuticalreview
    August 21, 2020
    United Therapeutics announced the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with ...
PharmaSources Customer Service